Coumarin

Coumarin

SCHEMBL453897

O=c1ccc2ccccc2o1.[NaH]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 11/20 0.95
▸ CA9 Q16790 11/20 0.95
▸ CA1 P00915 7/20 0.95
▸ CA3 P07451 7/20 0.95
▸ CA4 P22748 7/20 0.95
▸ CA7 P43166 7/20 0.95
▸ CA14 Q9ULX7 7/20 0.95
▸ CA5A P35218 6/20 0.95
▸ CA6 P23280 6/20 0.95
▸ CA5B Q9Y2D0 5/20 0.95
▸ CA2 P00918 5/20 0.95
▸ MCL1 Q07820 4/20 0.95
▸ TDP1 Q9NUW8 3/20 0.95
▸ LMNA P02545 3/20 0.95
▸ SOST Q9BQB4 1/20 0.95
▸ PGR P06401 2/20 0.55
▸ ALDH1A1 P00352 5/20 0.52
▸ HPGD P15428 5/20 0.52
▸ HSD17B10 Q99714 4/20 0.52
▸ KDM4E B2RXH2 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Coumarin SCHEMBL1038138 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL621751 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL6252 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL3441294 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL29385611 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL28886137 0.98 CA12 (1.00) CA12CA9CA1CA3CA4
Coumarin SCHEMBL6920202 0.95 CA12 (0.95) CA12CA9CA1CA3CA4
Coumarin SCHEMBL382038 0.95 CA12 (0.95) CA12CA9CA1CA3CA4
Coumarin SCHEMBL22721260 0.95 CA12 (0.95) CA12CA9CA1CA3CA4
Coumarin SCHEMBL3680680 0.95 CA12 (0.95) CA12CA9CA1CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117384259-A Cell penetrating peptides based on influenza virus M2 proteins 中国医学科学院基础医学研究所 2024-01-12 — — CN claimed
CN-112912386-B Cell penetrating peptides based on influenza virus M2 proteins 中国医学科学院基础医学研究所 2023-10-20 — — CN claimed
EP-4541275-A1 ANALYTE SENSOR, AND PREPARATION METHOD THEREFOR AND APPLICATION METHOD THEREOF Shanghai United Imaging Microelectronics Technology Co., Ltd. (CN) 2025-04-23 — — EP disclosed
CN-113861268-B Cell penetrating peptides and methods of making and using the same 恩特拉达治疗学股份有限公司 2025-04-01 — — CN disclosed
WO-2025050335-A1 ANALYTE SENSOR, AND PREPARATION METHOD THEREFOR AND APPLICATION METHOD THEREOF 上海联影微电子科技有限公司 2025-03-13 — — WO disclosed
CN-118215450-A System and method for coating bone material 华沙整形外科股份有限公司 2024-06-18 — — CN disclosed
CN-117866042-A Disulfide-containing cell penetrating peptides and methods of making and using the same 俄亥俄州国家创新基金会 2024-04-12 — — CN disclosed
CN-117467497-A Method for removing aflatoxin B1 in vegetable oil 河南工业大学 2024-01-30 — — CN disclosed
CN-117384259-A Cell penetrating peptides based on influenza virus M2 proteins 中国医学科学院基础医学研究所 2024-01-12 — — CN disclosed
CN-114773155-B Process for separating glycerin from biodiesel byproduct 宁波杰森绿色能源科技有限公司 2024-01-12 — — CN disclosed
CN-110114075-B Disulfide-containing cell penetrating peptides and methods of making and using the same 俄亥俄州国家创新基金会 2024-01-12 — — CN disclosed
US-20130231302-A1 ANTIMICROBIAL SOLUTIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-09-05 — — US disclosed
US-20130164363-A1 ANTIMICROBIAL FLUSH SOLUTIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-06-27 — — US disclosed
WO-2012034032-A2 ANTIMICROBIAL SOLUTIONS THE BOARD OF REGENTS OF UNBIVERSITY OF TEXAS SYSTEM (US) 2012-03-15 — — WO disclosed
US-20110201692-A1 ANTIMICROBIAL FLUSH SOLUTIONS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-08-18 — — US disclosed
US-20100055086-A1 Antimicrobial Flush Solutions RAAD ISSAM 2010-03-04 — — US disclosed
US-7601731-B2 Rapidly removing microorganisms from indwelling medical devices; active ingredient, alcohol and chelators and/or anticoagulants BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2009-10-13 — — US disclosed
EP-1644024-A2 ANTIMICROBIAL FLUSH SOLUTIONS Board of Regents, The University of Texas System (US) 2006-04-12 — — EP disclosed
US-20050013836-A1 Antimicrobial flush solutions BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2005-01-20 — — US disclosed
WO-2004108091-A2 ANTIMICROBIAL FLUSH SOLUTIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2004-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231302-A1 ANTIMICROBIAL SOLUTIONS UGCG, GANAB, GANC CA12 2201/4885CA9 2327/4885CA1 4000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback